Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another installment of The Health Kick Podcast.
In this episode Tim interviews Michael Harsh, non-executive director at Imagion Biosystems (ASX:IBX).
Imagion Biosystems is developing a diagnostic imaging tool called Magsense, which is based on injecting nanoparticles with magnetic fields to detect tumors such as breast cancers.
Listen to the podcast.
Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway
Highlights Dr Nina Webster appointed as IBX Non-Executive Director, bringing significant clinical development expertise and corporate experienceto the IBX Board ahead of HER2 Breast cancer